专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07635683B2 Quinoxalinyl tripeptide hepatitis C virus inhibitors 有权
标题翻译：喹喔啉三肽丙型肝炎病毒抑制剂
公开(公告)号：US07635683B2
公开(公告)日：2009-12-22
申请号：US11499917
申请日：2006-08-04
申请人： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/06
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

32. 发明申请

US20090047248A1 TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 失效
标题翻译：三唑基大环内酯类抗坏血酸C蛋白酶抑制剂
公开(公告)号：US20090047248A1
公开(公告)日：2009-02-19
申请号：US11835657
申请日：2007-08-08
申请人： Ying Sun , Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/4192 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/7056 , A61K38/21 , A61P31/00 , C07D487/04
CPC分类号： C07D487/04 , A61K31/4192 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/7056 , A61K38/21 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

33. 发明申请

US20090041721A1 ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS 失效
公开(公告)号：US20090041721A1
公开(公告)日：2009-02-12
申请号：US11836288
申请日：2007-08-09
申请人： Deqiang Niu , Yonghua Gai , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Yonghua Gai , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/40 , A61K31/4025 , A61K31/407 , A61K31/4709 , A61K31/7056 , A61K38/21 , A61P31/12 , C07D207/16 , C07D401/02 , C07D405/12 , C07D409/12 , C07D487/04
CPC分类号： C07D487/04 , A61K38/21 , A61K38/212 , C07D207/16 , C07D401/12 , C07D405/12 , C07D409/12 , C07K5/0804 , C07K5/0808 , A61K2300/00
摘要： The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明公开了式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

34. 发明申请

US20080317712A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：抗坏血酸乙酰胆碱和抗坏血酸乙酰胆碱酯酶蛋白酶抑制剂
公开(公告)号：US20080317712A1
公开(公告)日：2008-12-25
申请号：US12108628
申请日：2008-04-24
申请人： Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07D401/04 , A61K38/05 , C07D403/04 , A61P31/12 , C07D413/14
CPC分类号： C07D401/04 , A61K38/00 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

35. 发明授权

US08377872B2 Cyclic P3 tripeptide hepatitis C serine protease inhibitors 有权
标题翻译： Cyclic P3三肽丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US08377872B2
公开(公告)日：2013-02-19
申请号：US11740440
申请日：2007-04-26
申请人： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00 , A01N37/18
CPC分类号： A61K38/212 , A61K38/215 , C07K5/0821 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

36. 发明授权

US07662779B2 Triazolyl macrocyclic hepatitis C serine protease inhibitors 失效
标题翻译：三唑基大环丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US07662779B2
公开(公告)日：2010-02-16
申请号：US11835657
申请日：2007-08-08
申请人： Ying Sun , Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/12 , C07K5/12
CPC分类号： C07D487/04 , A61K31/4192 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/7056 , A61K38/21 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

37. 发明申请

US20080274080A1 AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
标题翻译： AZA-PEPTIDE MACROCYCLIC HEPATITIS C丝氨酸蛋白酶抑制剂
公开(公告)号：US20080274080A1
公开(公告)日：2008-11-06
申请号：US12108643
申请日：2008-04-24
申请人： Yat Sun Or , Deqiang Niu , Zhe Wang
发明人： Yat Sun Or , Deqiang Niu , Zhe Wang
IPC分类号： A61K31/407 , C07D487/04 , A61K31/498 , A61K38/21 , A61K31/7056 , A61P31/12 , A61K31/4709
CPC分类号： C07D487/04
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

38. 发明授权

US07407942B2 3,6-bridged 9,12-oxolides 失效
标题翻译： 3,6-桥联的9,12-草甘膦
公开(公告)号：US07407942B2
公开(公告)日：2008-08-05
申请号：US11435401
申请日：2006-05-16
申请人： Yat Sun Or , Deqiang Niu , Zhe Wang
发明人： Yat Sun Or , Deqiang Niu , Zhe Wang
IPC分类号： A61K31/70 , C07H17/08
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了具有抗菌性质的式（I）化合物或其药学上可接受的盐，酯或前药。本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

39. 发明申请

US20080032936A1 Quinoxalinyl tripeptide hepatitis C virus inhibitors 有权
标题翻译：喹喔啉三肽丙型肝炎病毒抑制剂
公开(公告)号：US20080032936A1
公开(公告)日：2008-02-07
申请号：US11499917
申请日：2006-08-04
申请人： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Yonghua Gai , Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/05 , C07K5/08
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

40. 发明授权

US07265094B2 9N-substituted 6-11 bicyclic erythromycin derivatives 失效
标题翻译： 9N-取代的6-11双环红霉素衍生物
公开(公告)号：US07265094B2
公开(公告)日：2007-09-04
申请号：US11031465
申请日：2005-01-07
申请人： Yao-Ling Qiu , Deqiang Niu , Zhe Wang , Ly Tam Phan , Yat Sun Or
发明人： Yao-Ling Qiu , Deqiang Niu , Zhe Wang , Ly Tam Phan , Yat Sun Or
IPC分类号： A61K31/70 , C07H17/08
CPC分类号： C07H17/08
摘要： The present invention discloses compounds of formula I, II, III, or IV, or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
摘要翻译：本发明公开了式I，II，III或IV的化合物或其外消旋物，对映异构体，区域异构体，盐，酯或前药：其表现出抗菌性质。本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。本发明还包括制备本发明化合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式